Serina Therapeutics Inc SER 深 滬
已收盤 02-06 16:00:00 美东时间
2.37
-0.100
-4.05%
華盛通- 最 高2.47
- 今 開2.47
- 成交量 34.95万股
- 最 低 2.11
- 昨 收 2.47
- 總市值 2527.38万
- 52周最高 7.92
- 市盈率 靜 --
- 換手率 3.28%
- 52周最低 1.7101
- 委 比 -40.85%
- 總股本 1066.41万
- 歷史最高 209.2615
- 量 比 0.45
- 振 幅 14.57%
- 歷史最低 1.7101
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why DarkIris Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Shares of DarkIris Inc (NASDAQ:DKI) rose sharply in pre-market trading after th...
02-02 18:17
Market-Moving News for January 29th
META: 10% | Meta Platforms shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 sales guidance above estimates. TSLA: 4% | Tesla Q4
01-29 20:22
What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?
Serina Therapeutics shares jumped nearly 35% after the FDA cleared its IND application for SER-252, advancing plans for a Phase 1b trial in advanced Parkinson's disease.
01-29 13:09
FDA Clears IND Application for Serina Therapeutics' SER-252 in Advanced Parkinson's Disease
FDA Clears IND Application for Serina Therapeutics' SER-252 in Advanced Parkinson's Disease Serina Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SER-252, an investigational therapy for advanced Parkinson's
01-29 05:03
Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares
Chief Scientific Officer Randall Moreadith Reports Disposal of Serina Therapeutics Inc. Common Shares Randall Moreadith, Chief Scientific Officer of Serina Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer:
01-24 01:35
Serina Therapeutics Receives New York Stock Exchange Noncompliance Notification, Gets Time Through Feb. 8 To Regain Compliance
Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease,
01-16 05:31
Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of AZZ Inc (NYSE:AZZ) rose in pre-market trading after the company repor...
01-08 17:25
Serina Therapeutics Submits Complete Response To FDA Clinical Hold Letter For SER-252, Lead Program For Advanced Parkinson's Disease
– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA
2025-12-11 05:34
Serina Therapeutics Q3 EPS $(0.45) Beats $(0.53) Estimate
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.53) by 15.09 percent. This is a 446.15 percent decrease over earnings of $0.13 per share from
2025-11-13 19:13
The FDA Placed A Clinical Hold On Serina Therapeutics' Investigational New Drug Application For SER-252, Serina's Lead Development Program For Advanced Parkinson's Disease, And Requested Additional Information Related To A Commonly Used Excipient In The Formulation
erina expects to receive the FDA's formal clinical-hold letter within 30 days and will provide an update once it has aligned with the FDA on next steps and timelines. In prior interactions, the FDA indicated support for
2025-11-03 19:11
